Insulet
(Nasdaq: PODD)
announced today that it began a limited market release of the Omnipod 5 with the Dexcom G7.
This marks the latest integration of Dexcom’s next-generation CGM into automated insulin delivery technology. Omnipod 5, Insulet’s newest patch pump offering, previously worked with the G6 in the U.S. It also recently integrated the system with Abbott’s FreeStyle Libre 2 Plus in Europe.
Insulet previously suggested that G7 integration would come early in 2024. In the company’s fourth-quarter earnings report — which included Street-beating results — the company confirmed the initial limited rollout began recently.
Shares of PODD fell nearly 7% at $183.50 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day up 0.6%.
Get the full story at our sister site, Drug Delivery Business News.